Toggle light / dark theme

U.S. company can keep hosting vast coronavirus-related project but must protect French citizens’ health data from American government, court rules.


A French court has ruled that Microsoft Corp. can continue hosting a government-run project aggregating citizens’ anonymous health data to use for AI-based research, but must guarantee no data will be sent to the U.S. or be shared with American intelligence authorities.

The ruling, handed down last week, contradicts the stance of France’s data protection authority, which told the court this month that any U.S. cloud provider could be forced to comply with U.S. surveillance laws and should therefore not be allowed to host sensitive health data. The regulator’s opinion could provide clues for other companies handling such data, legal experts say.

Companies are wrestling with tricky decisions about moving their data from the European Union to the U.S., following a court decision this summer that required personal data transferred there to include special guarantees against surveillance by the American government.

So now, there are AI doctors.


Machine learning is taking medical diagnosis by storm. From eye disease, breast and other cancers, to more amorphous neurological disorders, AI is routinely matching physician performance, if not beating them outright.

Yet how much can we take those results at face value? When it comes to life and death decisions, when can we put our full trust in enigmatic algorithms—“black boxes” that even their creators cannot fully explain or understand? The problem gets more complex as medical AI crosses multiple disciplines and developers, including both academic and industry powerhouses such as Google, Amazon, or Apple, with disparate incentives.

This week, the two sides battled it out in a heated duel in one of the most prestigious science journals, Nature. On one side are prominent AI researchers at the Princess Margaret Cancer Centre, University of Toronto, Stanford University, Johns Hopkins, Harvard, MIT, and others. On the other side is the titan Google Health.

FERNDALE, Mich. – Samples from Ferndale’s municipal water system have lead levels in the drinking water exceeding state standards, according to officials.

Oakland County Health Division (OCHD) was notified by the Michigan Department of Environment, Great Lakes, and Energy (EGLE) about the results from testing. Testing occurred as part of routine compliance sampling required by EGLE under Michigan’s Safe Drinking Water Act.

The OCHD is coordinating the distribution of free water filter kits to Ferndale residents who qualify on Oct. 28 from 3 to 6 p.m. at the Gary Kulick Community Center (1201 Livernois St, Ferndale, MI 48220).

An odd lump on Elizabeth Cowles Johnston’s breast prompted a Friday morning call to her primary care physician Rebecca Andrews at UConn Health.

Dr. Andrews quickly fit her in, and upon checking the lump sent her to Dr. Alex Merkulov, Section Head of Women’s Imaging at the Beekley Imaging Center at UConn Health for a mammogram and ultrasound. The following Monday she had a biopsy of her breast and by that Wednesday she had the diagnosis of breast cancer.

“It was all very quick,” says Johnston.

It looks like micro-plastics are now found inside human bodies.


Researchers found evidence of plastic contamination in tissue samples taken from the lungs, liver, spleen and kidneys of donated human cadavers.

“We have detected these chemicals of plastics in every single organ that we have investigated,” said senior researcher Rolf Halden, director of the Arizona State University (ASU) Biodesign Center for Environmental Health Engineering.

There’s long been concern that the chemicals in plastics could have a wide range of health effects ranging from diabetes and obesity to sexual dysfunction and infertility.

Food and Drug Administration (FDA) agrees to a trial using the LungFit™ system to treat COVID-19 patients

Applications pending with Health Canada and the Israel Ministry of Health to allow studies to be conducted using high concentration nitric oxide to treat COVID-19 patients

GARDEN CITY, N.Y., April 16, 2020 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO for the treatment of solid tumors, today announced that the U.S. Food and Drug Administration (FDA) agreed with the initiation of a clinical study in the U.S. using its LungFit™TM system to treat COVID-19 patients. Applications for funding are pending with the Biomedical Advance Research and Development Authority (BARDA), a division of Health and Human Services (HHS).

Seven performers selected to pursue novel USV concepts and enabling technologies.


DARPA has awarded seven contracts for work on Phase 1 of the NOMARS program, which seeks to simultaneously explore two competing objectives related to unmanned surface vessels (USV) ship design: the maximization of seaframe performance when human constraints are removed; and achieving sufficient vessel maintenance and logistics functionality for long endurance operations with no human crew onboard. NOMARS aims to disrupt conventional naval architecture designs through creative trade space explorations that optimize useable onboard room considering a variety of constraints. This should pave the way for more capable, affordable small warships that can be procured and maintained in large numbers.

Autonomous Surface Vehicles, LLC, Gibbs & Cox Inc., and Serco Inc. received Phase 1 Track A awards, and will work toward developing novel NOMARS demonstrator conceptual designs. These awards will focus on maximizing vessel performance gain across new design criteria, with potential considerations to include: unusual hull forms, low freeboard, minimizing air-filled volumes, innovative materials, repurposing or eliminating “human space” exploring distributed system designs, and developing architectures optimized for depot-maintenance.

Barnstorm Research Corporation and TDI Technologies, Inc. received Phase 1 Track B awards, and will develop robust approaches to ship health-monitoring via novel Self-Adaptive Health Management (SAHM) architectures, which will be pivotal to achieving NOMARS at-sea endurance and reliability objectives. InMar Technologies and Siemens Corporation also received Phase 1 Track B awards; the former will develop new techniques for morphing hull structures to maximize performance, while the latter will implement toolsets previously developed through the DARPA TRADES program to design optimized material structures for novel NOMARS ship concepts.

In 2016, I proposed LEO HTS Mega Constellation a viable solution for Australia’s broadband national coverage. I have been doing research on these constellations right from the beginning and they are inevitable!


Introduction

Utilizing the announced Lower Earth Orbit (LEO) satellites constellations of OneWeb, SpaceX, LeoSat & Samsung to provide high speed connectivity to entire Australian continent with performance better than fiber networks. This project can eliminate high cost NBN roll out to scattered populations and will considerably improve disaster management. Providing high speed connectivity for mobile communication, internet, high resolution TV broadcast as well as utilizing technologies like IoT & Cloud for improvement in security, education, health, agriculture, livestock farming, mineral resources, wildlife, and environment without any coverage black-spots. This network will not require any infrastructure installations and will help the Government to generate revenues by issuing spectrum licenses to local as well as foreign investors for providing services directly to the end user.

2011 Census

Census 2011

Source: Regional Statistics by ASGS, 2010–2014.